Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · Genome Medicine · 2017 · 3.7K citations · Full text

Medicine, Cancer Biology, Oncology +17

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day et al. · Clinical Cancer Research · 2009 · 3.2K citations

Medicine, Immunology, Oncology +17

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra et al. · The Lancet Oncology · 2016 · 1.7K citations

Medicine, Oncology, Pharmacotherapy +13

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17